The lack of tools to predict the development of skin adverse events (SkAE) after therapy with TNF blockers in IBD patients (Sridhar et al., 2018; Cossio et al., 2020) prompted us to investigate skin microbiota composition and serum biomarkers pattern in these patients. The gene discussed is TNF; the disease is inflammatory bowel disease.